Neurocrine Biosciences (NBIX) Stock Forecast & Price Target

Neurocrine Biosciences is an attractive investment opportunity due to the company's strong portfolio of therapies targeting a wide range of neurological and endocrine disorders, including their successful treatments for tardive dyskinesia and chorea associated with Huntington's disease. The recent acquisition of Soleno Therapeutics and their product VYKAT XR for Prader-Willi Syndrome adds further diversification to NBIX's revenue mix and is expected to be accretive to both revenue and non-GAAP EPS starting in 2026. The company also has a strong pipeline of drug candidates in various stages of development, providing potential for future growth. As a result, we believe NBIX is well-positioned for long-term success and we maintain a positive outlook on the stock.

Neurocrine Biosciences is likely to face challenges in achieving sustained revenue growth as their late-stage pipeline entails high risk CNS assets in indications that have a history of trial failures. Additionally, the integration of SLNO's lead program Vykat XR may not provide significant synergies and could increase SG&A expenses, which could impact profitability. Further, the potential for underperformance of existing drugs, such as Ingrezza, and the lack of growth levers after 2030 could limit the company's long-term prospects.